RxDoctor Payments Data

Neal Hermanowicz, MD

Neurology · Newport Beach, CANPI 1023198181

Payments from drug & device makers

$562,008in general payments, 2019–2025

Across 494 payments — averaging $1137.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$260K
  • Amneal Pharmaceuticals LLC$104K
  • Eli Lilly$67K
  • AbbVie$65K
  • Neurocrine Biosciences, Inc.$18K
  • MDD US Operations, LLC$12K
  • plus $37K from 15 others
$20,289in research payments, 2019–2025

Across 5 payments — averaging $4057.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Neurocrine Biosciences, Inc.$15K
  • Eli Lilly$2K
  • UCB, Inc.$2K

What the payments were for

  • Consulting fees$93,35222%
  • Speaking & faculty fees$282,86366%
  • Travel & lodging$44,66010%
  • Food & beverage$8,9012%
  • Education$1,1630%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$562,008 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$193,284
Medicare patients
563
Services billed
1,657

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate123$665,933
IngrezzaValbenazine Tosylate42$395,944
RytaryCarbidopa/Levodopa189$268,197
GocovriAmantadine Hcl79$175,410
NeuproRotigotine51$69,966
HorizantGabapentin Enacarbil19$34,126
Carbidopa-LevodopaCarbidopa/Levodopa842$24,972
MyrbetriqMirabegron16$14,462
Rivastigmine62$11,095
AmantadineAmantadine Hcl86$3,455
RivastigmineRivastigmine Tartrate55$3,063
Memantine Hcl87$2,770
Carbidopa11$2,724
Gabapentin81$2,278
Primidone95$2,015

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$259,608$665,933123 claims
Neurocrine Biosciences, Inc.Ingrezza$18,267$395,94442 claims
Amneal Pharmaceuticals LLCRytary$103,630$268,197189 claims
MDD US Operations, LLCGocovri$11,989$175,41079 claims
UCB, Inc.Neupro$9,917$69,96651 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.

Other neurology in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →